×
For best experience we recommend to activate Javascript in your browser.
Recombinant Adenosine A2a Receptor antibody
The Human Monoclonal anti-Adenosine A2a Receptor antibody has been validated for ELISA, FACS, BLI, Func and SPR. It is suitable to detect Adenosine A2a Receptor in samples from Human.
Quick Overview for Recombinant Adenosine A2a Receptor antibody (ABIN7581229)
Target
See all Adenosine A2a Receptor (ADORA2A) Antibodies
Adenosine A2a Receptor (ADORA2A)
Antibody Type
Recombinant Antibody
Reactivity
All reactivities for Adenosine A2a Receptor antibodies
Human
Host
All hosts for Adenosine A2a Receptor antibodies
Human
Clonality
All clonalities for Adenosine A2a Receptor antibodies
Monoclonal
Conjugate
All conjugates for Adenosine A2a Receptor antibodies
This Adenosine A2a Receptor antibody is un-conjugated
Application
All applications for Adenosine A2a Receptor antibodies
ELISA, Flow Cytometry (FACS), Bio-Layer Interferometry (BLI), Functional Studies (Func), Surface Plasmon Resonance (SPR)
Clone
3F6-9G5
Product Details anti-Adenosine A2a Receptor Antibody
(hide)
Expression System
CHO Cells
Purpose
Anti-AA2AR / Adenosine A2aR Reference Antibody (3F6-9G5)
Characteristics
Anti-AA2AR / Adenosine A2aR Reference Antibody (3F6-9G5) is expressed from CHO. The heavy chain type is IgG1, and the light chain type is hukappa. It has a predicted MW of 146.66 kDa.
Purity
>95 %
Isotype
IgG1
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Lyophilized
Concentration
1 mg/mL
Buffer
25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
Storage
4 °C,-80 °C
Storage Comment
+4°C,-80°C
Target Details for Adenosine A2a Receptor
(hide)
Target
Adenosine A2a Receptor (ADORA2A)
Alternative Name
AA2AR
Molecular Weight
146.66 kDa
UniProt
P29274
Pathways
Neurotrophin Signaling Pathway , cAMP Metabolic Process , Synaptic Membrane , Feeding Behaviour , Cancer Immune Checkpoints
Recently viewed
(hide)
Chat with us , powered by LiveChat